Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of FT218 in the Treatment of Idiopathic Hypersomnia (IH)

NCT06525077 is registered in ClinicalTrials.gov with Avadel as lead sponsor.

NCT NCT06525077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06525077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of FT218 in the Treatment of Idiopathic Hypersomnia (IH)
Lead sponsor
Avadel
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2024
Completion date
March 25, 2026
Enrollment
157 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic hypersomnia